Skip to main content
SpringerLink
Log in

5-Aminosalicylate Therapy

  • Chapter
  • First Online:
Pediatric Inflammatory Bowel Disease

  • 1551 Accesses

Abstract

Aminosalicylates are commonly used medications for the treatment of mild-to-moderate inflammatory bowel disease. The exact mechanism of action is unknown, although it is thought that aminosalicylates have more of a topical effect on the gastrointestinal mucosa rather than a systemic one. 5-ASA is a well-established first-line therapy for mild-to-moderate ulcerative colitis in the adult population, and remains an important option for children with mild-to-moderate UC. However, its use in pediatric Crohn’s disease is controversial given the lack of data supporting its efficacy. Few studies have addressed the use of 5-ASA in the pediatric population. In general, aminosalicylates are well tolerated in children with few dose-related side effects. An important step forward can be expected from the NIH funded Predicting Response to Standardized Pediatric Colitis Therapy (PROTECT) Study.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 259.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;23:841–55.

    Article  PubMed  CAS  Google Scholar 

  2. Sandborn WJ. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord. 2006;6:97–105.

    PubMed  Google Scholar 

  3. Campregher C, Gasche C. Aminosalicylates. Best Pract Res Clin Gastroenterol. 2011;25:535–46.

    Article  PubMed  CAS  Google Scholar 

  4. Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 2011;63:629–42.

    PubMed  CAS  Google Scholar 

  5. Azadkhan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol. 1982;13:523–8.

    PubMed  CAS  Google Scholar 

  6. Escher JC, Taminiau J, Nieuwenhuis E, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34–58.

    Article  PubMed  Google Scholar 

  7. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid—new evidence. Aliment Pharmacol Ther. 2006;24 Suppl 1:2–9.

    Article  PubMed  CAS  Google Scholar 

  8. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999;274:26448–53.

    Article  PubMed  CAS  Google Scholar 

  9. Girnun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA. 2002;99:13771–6.

    Article  PubMed  CAS  Google Scholar 

  10. Lacuccu M, de Silva S, Ghosh S. Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol. 2010;24:127–33.

    Google Scholar 

  11. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008;134:688–95.

    Article  PubMed  CAS  Google Scholar 

  12. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol. 2000;95:3343–5.

    Article  PubMed  CAS  Google Scholar 

  13. Cohen RD, Lichtenstein GR, Safdi AV. 5-ASA treatment for ulcerative colitis: what’s on the horizon? Gastroenterol Hepatol. 2008;4 Suppl 24:5–14.

    Google Scholar 

  14. Harris MS, Lichtenstein GR. Review article: deliver and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2011;33:996–1009.

    Article  PubMed  CAS  Google Scholar 

  15. Prantera C, Rizzi M. 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol. 2009;15:4353–5.

    Article  PubMed  CAS  Google Scholar 

  16. Baumgart DC, Sandhorn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–57.

    Article  PubMed  CAS  Google Scholar 

  17. Sandhorn WJ. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol. 2008;42:338–44.

    Article  Google Scholar 

  18. Kornbluth A, Sachar DB. Practice parameters committee of the American college of gastroenterology. Ulcerative colitis practice guidelines in adults (update). Am J Gastroenterol. 2004;99:1371–85.

    Article  PubMed  Google Scholar 

  19. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000543.

    Google Scholar 

  20. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systemic review and meta-analysis. Am J Gastroenterol. 2011;106:601–16.

    Article  PubMed  CAS  Google Scholar 

  21. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115.

    Google Scholar 

  22. Ford AC, Khurram JK, Achkar JP, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;doi:10.1038/ajg.2011.410.

    Google Scholar 

  23. Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing—ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011;33:672–8.

    Article  PubMed  CAS  Google Scholar 

  24. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000544.

    Google Scholar 

  25. Mantzaris GJ, Hatzis A, Petraki K, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum. 1994;37:58–62.

    Article  PubMed  CAS  Google Scholar 

  26. Ford AC, Khurram JK, Sandborn WJ, et al. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:513–9.

    Google Scholar 

  27. Kane S, Katz S, Jamal MM. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis. 2012;18:1026–33.

    Google Scholar 

  28. Ford AC, Khan KJ, Sandborn WJ, et al. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:2070–7.

    Article  PubMed  CAS  Google Scholar 

  29. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Ransomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893–902.

    Article  PubMed  CAS  Google Scholar 

  30. Heyman MB, Kierkus J, Spenard J, et al. Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm Bowel Dis. 2010;16:1931–9.

    Article  PubMed  Google Scholar 

  31. Romano C, Famiani A, Comito D, et al. Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. J Pediatr Gastroenterol Nutr. 2010;50:385–9.

    PubMed  CAS  Google Scholar 

  32. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2010;(12):CD008870.

    Google Scholar 

  33. Singleton JW, Summers RW, Kern F, et al. A trial of sulfasalazine as adjunctive therapy in crohn’s disease. Gastroenterology. 1979;77:887–97.

    PubMed  CAS  Google Scholar 

  34. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn’s disease study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–66.

    PubMed  CAS  Google Scholar 

  35. Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:617–29.

    Article  PubMed  CAS  Google Scholar 

  36. Scholmerich J, Jenss H, Hartmann F, et al. Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn’s disease. Can J Gastroenterol. 1990;4:446–51.

    Google Scholar 

  37. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339:370–4.

    Article  PubMed  CAS  Google Scholar 

  38. Mesker T, van Rheenen PF, Norbruis OF, et al. Pediatric Crohn’s disease activity at diagnosis, its influence on pediatrician’s prescribing behavior, and clinical outcome 5 years later. Inflamm Bowel Dis. 2009;15:1670–7.

    Article  PubMed  Google Scholar 

  39. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):CD003715.

    Google Scholar 

  40. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–63.

    PubMed  CAS  Google Scholar 

  41. Ford AC, Khan KJ, Talley NJ, et al. 5-aminosalicylates prevent relapse of Crohn’s disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:413–20.

    Article  PubMed  CAS  Google Scholar 

  42. Gordon M, Naidoo K, Thomas AG, et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2011;(1):CD008414.

    Google Scholar 

  43. Wasan SK, Farraye FA. Do 5-ASAs prevent colorectal neoplasia in patients with ulcerative colitis? Still no answers. Inflamm Bowel Dis. 2010;16:358–60.

    PubMed  Google Scholar 

  44. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylatic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106:731–6.

    Article  PubMed  CAS  Google Scholar 

  45. Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:367–71.

    Article  PubMed  Google Scholar 

  46. Van Staa TP, Card T, Logan RF, et al. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573–8.

    Article  PubMed  Google Scholar 

  47. Tang J, Sharif O, Pai C, et al. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci. 2010;55:1696–703.

    Article  PubMed  CAS  Google Scholar 

  48. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74.

    Article  PubMed  Google Scholar 

  49. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–45.

    Article  PubMed  Google Scholar 

  50. Munding J, Ziebarth W, Pox CP, et al. The influence of 5-amionsalicylic acid on the progression of colorectal adenomas via beta-catenin signaling pathway. Carcinogenesis. 2012;33:637–43.

    Google Scholar 

  51. Moum B. Which are the 5-ASA compound side effects and how is it possible to avoid them? Inflamm Bowel Dis. 2009;15:1438–47.

    Article  Google Scholar 

  52. Baker DE, Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Rev Gastroenterol Disord. 2004;4:86–91.

    PubMed  Google Scholar 

  53. Ransford RA, Langman MJS. Sulphasalazine and msalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536–9.

    Article  PubMed  CAS  Google Scholar 

  54. Rao SC, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalzine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol. 1987;22:332–6.

    Article  PubMed  CAS  Google Scholar 

  55. Barden L, Lipson A, Pert P, et al. Mesalazine in childhood inflammatory bowel disease. Aliment Pharmacol Ther. 1989;3:597–603.

    Article  PubMed  CAS  Google Scholar 

  56. D’Agata ID, Vanounou T, Seidman E. Mesalamine in pediatric inflammatory bowel disease: a 10-year experience. Inflamm Bowel Dis. 1996;2:229–35.

    Article  Google Scholar 

  57. Heyman MB, Klerkus J, Spenard J, et al. Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm Bowel Dis. 2010;16:1931–9.

    Article  PubMed  Google Scholar 

  58. Mogadam M, Dobbins 3rd WO, Korelitz BI, et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 1981;80:72.

    PubMed  CAS  Google Scholar 

  59. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology. 1993;105:1057.

    PubMed  CAS  Google Scholar 

  60. Bell CM, Habal FM. Safety of topical 5-aminosalicylic acid in pregnancy. Am J Gastroenterol. 1997;92:2201.

    PubMed  CAS  Google Scholar 

  61. Ito S, Blajehman A, Stephenson M, et al. Prospective follow-up of adverse reaction in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168:1393–9.

    PubMed  CAS  Google Scholar 

  62. Nelis GF. Diarrhea due to 5-aminosalicylic acid in breast milk. Lancet. 1989;1:383.

    Article  PubMed  CAS  Google Scholar 

  63. Moshkovska T, Stone MA, Clatworthy J, et al. An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements. Aliment Pharmacol Ther. 2009;30:1118–27.

    Article  PubMed  CAS  Google Scholar 

  64. Higgins PDR, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29:247–57.

    Article  PubMed  CAS  Google Scholar 

  65. Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol. 2008;33:867–74.

    Article  PubMed  Google Scholar 

  66. Kane SV, Sumner M, Solomon D, et al. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011;56:3463–70.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Gastroenterology, Hepatology & Nutrition, Medical College of Wisconsin, Children’s Hospital of Wisconsin, Milwaukee, WI, 53226-0509, USA

    Michael Stephens MD

  2. Department of Pediatric Gastroenterology, Hepatology & Nutrition, Children’s Hospital of Wisconsin, Milwaukee, WI, USA

    Alisha M. Mavis MD

Authors
  1. Michael Stephens MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alisha M. Mavis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Stephens MD .

Editor information

Editors and Affiliations

  1. Perelman School of Medicine, The Children’s Hospital of Philadelphia, University of Pennsylvania, 34th St. & Civic Ctr. Blvd., Philadelphia, 19104, Pennsylvania, USA

    Petar Mamula

  2. School of Medicine--Greenville, Pediatric Gastroenterology & Nutrition, University of South Carolina, 200 Patewood Drive, Suite A-140, Greenville, 29615, South Carolina, USA

    Jonathan E. Markowitz

  3. Perelman School of Medicine, The Children's Hospital of Philadelphia, University of Pennsylvania, 34th St. & Civic Ctr. Blvd., Philadelphia, 19104, Pennsylvania, USA

    Robert N. Baldassano

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Stephens, M., Mavis, A.M. (2013). 5-Aminosalicylate Therapy. In: Mamula, P., Markowitz, J., Baldassano, R. (eds) Pediatric Inflammatory Bowel Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5061-0_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5061-0_26

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5060-3

  • Online ISBN: 978-1-4614-5061-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation